Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ans – page 14

1 400 clinical trials in Ans, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ans at a glance
1 400
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 400 trials in Ans

Open in trial search

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Phase II Study of Intravenous Tarlatamab for Patients with Asymptomatic Brain Metastases from Small Cell Lung Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:University Hospital Maastricht

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Phase 2 Study of Rinatabart Sesutecan with Pegfilgrastim in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Asthma

Recruiting

A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Obesity+2

Recruiting

Study of the efficacy and safety of Eloralintide in adults with knee osteoarthritis and overweight or obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents with juvenile idiopathic arthritis.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ans

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. The research explores innovative approaches to manage functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Acid Reflux Treatment

This primary care study evaluates different therapeutic approaches, including on-demand medication use and alternative treatment formulations, to improve patient outcomes in digestive health management.

02 Primary Care Innovation

Groundbreaking research in medication management strategies, specifically targeting long-term PPI use in primary care settings. The study compares various approaches to reduce unnecessary medication dependency.

  • Medication De-prescribing
  • Patient-Centered Care
  • Treatment Optimization

The research aims to establish more effective protocols for managing common digestive conditions while minimizing long-term medication use.

03 Therapeutic Alternatives

Investigation into alternative treatment options for managing heartburn and related gastrointestinal conditions. The study explores the effectiveness of different therapeutic approaches.

  • Alternative Treatments
  • Symptom Management
  • Treatment Comparison

This research evaluates the comparative effectiveness of various treatment strategies, including alginate formulations and flexible dosing schedules.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.